Bladder Cancer
The types of bladder cancer are: non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC) , and the majority of newly diagnosed patients have NMIBC (70% to 85%). This is an important distinction, as NMIBC allows the patient bladder-sparing options for the treatment of bladder tumors. To help clarify between the two categories of bladder cancer, it is important to review the three histological layers of the bladder.
The first layer of the bladder is the urothelium , the second layer is the lamina propria (suburethral loose connective tissue), and the third layer is the muscularis propria . Cancers that affect the urothelium or lamina propria are NMIBC, and those that invade the muscularis propria are MIBC.
Almost 80% of patients with bladder cancer have noninvasive muscle disease at the time of diagnosis. Characteristics of this cancer are high recurrence rates after transurethral resection and a high risk of progression to muscle invasive disease.
Signs and symptoms
Often times, bladder cancer can be detected early as the signs and symptoms are more apparent than others in other types of cancer.
- Blood in the urine
- Changes in urinary habits or symptoms of irritation
- Symptoms of advanced bladder cancer:
- - Not being able to urinate
- - Pain on one side of the lower back (bladder pains)
- - Loss of appetite and weight loss
- - Tiredness or weakness
- - Swelling in the feet
- - Bone pain
If you notice any of the symptoms, see a health professional.
Treatments
Although intravesical chemotherapy and immunotherapy can significantly decrease the rates of recurrence and progression, they still represent the main challenge in this field and more effective therapies are needed.
Particularly challenging is the bladder cancer treatment of patients with high-risk tumors according to the European Organization for Research and Treatment of Cancer (EORTC) scoring system.
Many approaches have been used to enhance the antitumor effects of intravesical chemotherapy. Several studies have shown promising results combining intravesical mitomycin-C (MMC) with hyperthermia (intravesical thermochemotherapy treatment) . Hyperthermia of the bladder wall has been shown to enhance penetration of MMC into the deep bladder wall and may offer anticancer benefits over instillation of chemotherapy alone.
We are Grupo CRYO, a company specialized in fighting cancer.